Clinical Trial VICCTHN1297

Title

A Single-Arm Phase 2 Study of BMS-936558 in Subjects with Advanced or Metastatic Squamous Cell Non-Small Cell Lung Cancer Who have Received at Least Two Prior Systemic Regimens

Principal Investigator(s)

Leora Horn

Details

  • Protocol No. VICCTHN1297
  • Open Date: 02/07/2013
  • Staging: Phase II
  • Age Group: Adults
  • Scope: National
  • Objective: To assess the clinical activity of BMS-936558, as measured by the investigator-assessed objective response rate (ORR), in subjects with advanced or metastatic squamous cell NSCLC who have progressed during or after first-line platinum doublet chemotherapy and at least one US FDA or EMA-approved subsequent line of systemic therapy
  • Disease Sites: Lung
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: MDX-1106 (BMS-936558)
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01721759
  • Secondary Protocol No: CA209063

Description

Eligibility

Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.